---

---

---

---

Science Current Events and Science News RSS Feeds

---

---

Email a Friend Printer Friendly

Therapy For Mice With Prion Disease Could Offer Benefit To Human Beings With CJD

July 17, 2002

Authors of a fast-track research letter in this week's issue of THE LANCET describe a therapeutic treatment which increased the survival time for mice with prion disease. These results could represent a new approach to treating CJD in human beings.

The lack of an immune response to prions-the infectious proteins that cause scrapie, bovine spongiform encephalopathy (BSE), and Creutzfeldt-Jakob disease (CJD)-might be related to the fact that these agents do not contain nucleic acids (genetic material).

Hans Kretzschmar from Ludwig-Maximilians University and colleagues from the Technical University Munich, Germany, and Coley Pharmaceuticals, aimed to use genetic material (a specific type of nucleotide arrangement called CpG oligodeoxynucleotides) as a form of disease treatment after prion infection in mice. CpG oligodeoxynucleotides have previously been shown to stimulate the immune response.

The investigators inoculated 24 healthy mice with brain extracts from mice infected with scrapie prions, and then injected CpG oligodeoxynucleotides. This procedure resulted in 38% longer survival times than a control group that were injected with saline solution; longer survival times occurred when CpG oligodeoxynucleotides were given repeatedly over a three-week period.

Hans Kretzschmar comments: "The most likely explanation is the stimulation of TLR9-expressing cells of the innate immune system such as macrophages, monocytes, and dendritic cells. CpG oligodeoxynucleotides have not been shown to have adverse effects to human health and could therefore be considered as a therapeutic choice after prion infection."

In an accompanying Commentary (p 184), George Carlson from the McLaughlin Research Institute, USA, states that the approach of Kretzschmar and colleagues is reasonable, and concludes: "Development of improved diagnostics and postexposure prophylaxis are urgently needed given the unknown prevalence of subclinical prion infection associated with the BSE outbreak."

Lancet